| US 7,592,445 B2 | ||
| Non-nucleotide composition and method for inhibiting platelet aggregation | ||
| Robert Plourde, Jr., Chapel Hill, N.C. (US); Sammy R. Shaver, Chapel Hill, N.C. (US); James G. Douglass, III, Apex, N.C. (US); Paul S. Watson, Carrboro, N.C. (US); José L. Boyer, Chapel Hill, N.C. (US); Chi Tu, San Diego, Calif. (US); Melwyn A. Abreo, Jamul, Calif. (US); Lorenzo J. Alfaro-Lopez, San Marcos, Calif. (US); Yangbo Feng, Palm Beach Gardens, Fla. (US); Daniel F. Harvey, San Diego, Calif. (US); and Tatyana V. Khasonova, San Diego, Calif. (US) | ||
| Assigned to Inspire Pharmaceuticals, Inc., Durham, N.C. (US) | ||
| Filed on Jan. 04, 2008, as Appl. No. 11/969,539. | ||
| Application 11/969539 is a division of application No. 11/124619, filed on May 05, 2005, granted, now 7,335,648. | ||
| Application 11/124619 is a continuation in part of application No. 10/971766, filed on Oct. 21, 2004, granted, now 7,368,438. | ||
| Claims priority of provisional application 60/513845, filed on Oct. 21, 2003. | ||
| Prior Publication US 2008/0103304 A1, May 01, 2008 | ||
| Int. Cl. C07H 19/16 (2006.01); A01N 43/04 (2006.01); A61K 31/70 (2006.01) | ||
| U.S. Cl. 536—27.3 [514/46] | 12 Claims |
1. A compound of Formula III, or a pharmaceutically acceptable salt thereof:
 wherein Ra═Rc═H;
Rb is selected from the group consisting of: hydrogen, C1-8 alkyl, C3-7 cycloalkyl, aralkyl, and aryl;
Rd and Rd′ are independently selected from the group consisting of: H, C1-8 alkyl, and C3-7 cycloalkyl;
Re is absent;
Rf and Rg are independently selected from the group consisting of: —H, halogen, C1-8 alkyl, and C3-7 cycloalkyl;
Rh is H, alkyl, aryl, or aralkyl;
G is O;
J is carbon;
A1 is O;
D is O;
X1 is selected from the group consisting of: N and C-M; and
M is —H, halogen, or —[(CO)OR], and R is H, C1-8 alkyl, C3-7 cycloalkyl, aralkyl, or aryl.
|